MaxCyte to delist shares from London AIM, maintains Nasdaq listing

MaxCyte, Inc. (NASDAQ:MXCT), currently trading at $2.23 with a market capitalization of $239 million, announced Wednesday that it has applied to the London Stock Exchange (LON:LSEG) to cancel the admission of its common stock from trading on the AIM market. The company stated that the AIM delisting is expected to take effect at 7:00 a.m. U.K. time on Thursday, with the last day of trading on AIM being Wednesday. The stock has seen significant pressure recently, declining over 46% in the past six months and trading near its 52-week low of $2.01.

According to the company’s statement, this action will not affect the trading of MaxCyte’s shares on the Nasdaq Global Select Market, where they will continue to be listed under the ticker symbol MXCT.

The announcement was made as part of a press release included in a filing with the U.S. Securities and Exchange Commission.

In other recent news, MaxCyte, Inc. reported its first-quarter 2025 earnings, revealing a revenue of $10.4 million, which exceeded the forecasted $9.05 million. The company’s earnings per share (EPS) were -$0.10, slightly better than the anticipated -$0.11. Despite the positive earnings surprise, BTIG analyst Mark Massaro adjusted the price target for MaxCyte to $5.00 from $6.00, while maintaining a Buy rating on the stock. This adjustment reflects current macroeconomic challenges and funding uncertainties within the biopharmaceutical industry. MaxCyte shareholders have also approved an amendment to the company’s 2022 Equity Incentive Plan, increasing the authorized shares by 2,950,000, and supported the delisting from the AIM market of the London Stock Exchange. Additionally, MaxCyte reaffirmed its revenue guidance for 2025, citing confidence in its strategic initiatives and operational efficiencies. The company continues to focus on expanding its presence in the cell and gene therapy market, leveraging its premier technology in non-viral gene editing. Furthermore, MaxCyte elected three Class I directors to its board and ratified the selection of CohnReznick LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.